Stay Alert for Tendon Problems With Aromatase Inhibitors

April 2023

Health Canada is warning about the risk of tendon disorders with aromatase inhibitors (anastrozole, exemestane, letrozole).

Product monographs for these meds already caution about the risk of tendon sheath inflammation (tenosynovitis) of the hands.

Now the warning will expand to include the risk of tendonitis and tendon rupture...affecting upper and lower limbs.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

COVID-19 Share the Latest Guidance About COVID-19 Vaccines
COVID-19 Help Patients Cope With Long COVID
Menopause Clarify Options to Manage Vaginal Menopausal Symptoms
Insulin Answer FAQs About Insulin for Type 2 Diabetes
Antibiotics Put Concerns of Seizure Risk With Cephalosporins in Perspective
Pain Management Expect to See More Buprenorphine for Chronic Pain
Med Safety Stay Alert for Tendon Problems With Aromatase Inhibitors
Cardiology Be Ready for Camzyos for Obstructive Hypertrophic Cardiomyopathy
Medication Errors Help Ensure Ear Meds Aren’t Put in the Eyes